BURLINGTON, N.C. , Aug. 27, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, Sept. 9, at 7:45 am ET. A live audio webcast of the fireside chat will be available via the Company Investor... Read More

Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C. , Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the availability of the Lumipulse® pTau-217/Beta Amyloid 42 Ratio, the first blood-based in-vitro diagnostic (IVD) test cleared by the U.S. Food and Drug Administration (FDA) to aid in the... Read More

Test Finder interprets provider questions in context to deliver curated, clinically relevant results, going beyond traditional search Developed in collaboration with Amazon Web Services, Test Finder is now available on Labcorp.com BURLINGTON, N.C. , July 30, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Test Finder , a... Read More

First-and-only test of its kind approved under new European Union regulations expands access to personalized cancer care for patients across the EU BURLINGTON, N.C. , July 29, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today PGDx elio™ tissue complete has been CE-marked under the European Union's (EU) new In Vitro Diagnostic Regulation (IVDR). It is... Read More

Raises Full-Year Guidance Financial results from Operations for second quarter 2025 versus second quarter 2024: Revenue: $3.53 billion versus $3.22 billion Diluted EPS: $2.84 versus $2.43 Adjusted EPS: $4.35 versus $3.94 Raised Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance: Revenue guidance narrowed to 7.5% to 8.6%; midpoint raised by 70 basis points Adjusted EPS range narrowed to $16.05 to $16.50 ; midpoint... Read More

BURLINGTON, N.C. , July 10, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on September 11, 2025 , to stockholders of record as of the close of business on August 28, 2025 . About Labcorp Labcorp (NYSE: LH) is a... Read More

BURLINGTON, N.C. , June 26, 2025 /PRNewswire/ -- Labcorp Holdings Inc . (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2025 before the market opens on Thursday, July 24, 2025 . The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying... Read More

New offering delivers convenient, comprehensive lab testing solutions for functional medicine, integrative medicine and primary care providers BURLINGTON, N.C. , June 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp Whole Health Solutions to support the growing needs of functional medicine, integrative medicine and primary... Read More

New test offerings target solid tumors and hematologic malignancies Enhanced biopharma services support accelerated clinical trials and companion diagnostic development BURLINGTON, N.C. , May 30, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology portfolio. The additions include new test offerings for solid... Read More

BURLINGTON, N.C. , May 8, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that its Annual Meeting of Shareholders will be webcast live on May 15 at 9:00 a.m. ET and can be viewed online on the Labcorp Investor Relations website . An archived replay of the webcast will be available for one year. About Labcorp Labcorp (NYSE: LH) is a global leader of... Read More

Updates Full-Year Guidance Results from Operations for first quarter 2025 versus first quarter last year: Revenue: $3.35 billion versus $3.18 billion Diluted EPS: $2.52 versus $2.69 Adjusted EPS: $3.84 versus $3.68 Reaffirmed Revenue and Free Cash Flow guidance, raised midpoint of adjusted EPS: Revenue guidance of 6.7% to 8.0% Adjusted EPS range of $15.70 to $16.40 ; midpoint raised $0.05 Free Cash Flow of $1.10 billion to... Read More

Labcorp ® Plasma Detect™ now available for clinical use to assess risk of recurrence in stage III colon cancer patients FDA-authorized liquid biopsy assay PGDx elio ® plasma focus™ Dx now available to support treatment selection BURLINGTON, N.C. , April 23, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology... Read More

BURLINGTON, N.C. , April 10, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on June 11, 2025 , to stockholders of record as of the close of business on May 29, 2025 . About Labcorp Labcorp (NYSE: LH) is a global... Read More

Labcorp's pTau-217/Beta Amyloid 42 Ratio blood test meets the performance criteria to confirm amyloid pathology consistent with Alzheimer's disease BURLINGTON, N.C. , April 2, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide launch of its pTau-217/Beta Amyloid 42 Ratio , a powerful new blood-based biomarker test to aid in the... Read More

New offering expands screening options for cervical cancer and sexually transmitted infections (STIs), including chlamydia, gonorrhea, trichomonas or mycoplasma genitalium (Mgen) BURLINGTON, N.C. , April 1, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer nationwide a U.S. Food and Drug Administration (FDA) approved human... Read More

BURLINGTON, N.C. , March 31, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2025 before the market opens on Tuesday, April 29, 2025 . The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying... Read More

Transaction to extend Labcorp's leadership in oncology and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI , March 11, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today that they have entered into an... Read More

Labcorp® Plasma Complete TM offers oncologists a highly sensitive and specific genomic profiling solution from a simple blood draw BURLINGTON, N.C. , Feb. 24, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the clinical availability of Labcorp® Plasma Complete TM , a circulating tumor DNA (ctDNA)-based comprehensive genomic profiling solution for... Read More

Company Provides 2025 Guidance Results from Continuing Operations versus last year: Revenue: Q4 of $3.33 billion vs $3.03 billion ; Full year of $13.01 billion vs $12.16 billion Diluted EPS: Q4 of $1.70 vs $(1.95) ; Full year of $8.84 vs $4.33 Adjusted EPS: Q4 of $3.45 vs $3.30 ; Full year of $14.57 vs $13.56 Free Cash Flow: Q4 of $665.1 million vs $412.4 million ; Full year of $1.10 billion vs $748.7 million Announced 10... Read More

BURLINGTON, N.C. , Jan. 10, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that the company will participate in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14 , at 3:45 p.m. (PT). A live audio webcast of the fireside chat will be available via the Company Investor Relations website at ir.Labcorp.com and... Read More

BURLINGTON, N.C. , Jan. 8, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 12, 2025 , to stockholders of record as of the close of business on February 27, 2025 . About Labcorp Labcorp (NYSE: LH) is a... Read More

BURLINGTON, N.C. , Jan. 8, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth quarter of 2024 before the market opens on Thursday, February 6, 2025 . The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying... Read More

New test supports public health preparedness efforts and testing infrastructure amid multistate outbreak of H5 bird flu in poultry and dairy cows BURLINGTON, N.C. , Dec. 17, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the commercial availability of its new H5 bird flu molecular test to aid in the diagnosis of human infection with H5 bird flu.... Read More

Research to be presented in a joint poster session with Labcorp at the 2024 San Antonio Breast Cancer Symposium BOSTON and BURLINGTON, N.C. , Nov. 26, 2024 /PRNewswire/ -- Outcomes4Me Inc ., the developer of the first and only end-to-end, actionable cancer platform, announced today it has been selected to present the results of a biomarker awareness study, conducted with Labcorp , a global leader of innovative and... Read More

Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C. , Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024 , as Executive Vice President and Chief Financial... Read More

Collaboration to leverage Praia Health’s technology and Labcorp’s comprehensive testing capabilities to streamline and personalize patient experience CHICAGO & BURLINGTON, N.C. / Nov 04, 2024 / Business Wire / Praia Health , the consumer experience orchestration platform for health systems, is pleased to announce it has secured a strategic investment from the Labcorp Venture Fund and will collaborate with Labcorp, a global... Read More

Updates Full-Year Guidance Results from Continuing Operations for third quarter 2024 versus last year: Revenue: $3.28 billion versus $3.06 billion Diluted EPS: $2.00 versus $2.11 Adjusted EPS: $3.50 versus $3.38 Free Cash Flow: $162 million versus $171 million Updated Full-Year 2024 Guidance: Revenue range of 6.6% to 7.3%; midpoint unchanged Adjusted EPS range of $14.30 to $14.70 ; midpoint down $0.10 , due to the negative... Read More

As syphilis cases surge nationwide, the collaboration will bring the First To Know ® over-the-counter test to clinicians and patients across professional and hospital settings SPRINGDALE, Ark. / Oct 16, 2024 / Business Wire / NOWDiagnostics, Inc. (NOWDx), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostic... Read More

Labcorp to serve as the exclusive NOWDiagnostics (NOWDx) distributor for clinical testing in the U.S., offering First to Know® Syphilis Test nationwide BURLINGTON, N.C. , Oct 10, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it has expanded its... Read More

BURLINGTON, N.C. , Oct. 10, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on December 13, 2024 , to stockholders of record as of the close of business on November 26, 2024 . About Labcorp Labcorp (NYSE: LH) is a global leader... Read More

BURLINGTON, N.C. , Sept. 24, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the third quarter of 2024 before the market opens on Thursday, October 24, 2024 . The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial... Read More

New solution is the first holistic program available in a digital app to help women manage the postpartum period BOSTON , Sept. 18, 2024 /PRNewswire/ -- Ovia Health by Labcorp (Ovia) today announced the expansion of its women's health solutions to include a personalized, comprehensive Postpartum Experience – a 12-month program... Read More

BURLINGTON, N.C. , Sept. 16, 2024 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH) (Labcorp) announced today that its wholly owned subsidiary, Laboratory Corporation of America Holdings (LCAH), has priced its offering of $2,000,000,000 in senior notes (the Offering). The Offering consists of three tranches: $650,000,000 aggregate principal amount of 4.350% Senior Notes due 2030 (the 2030 Notes), $500,000,000 aggregate... Read More

Enhances Labcorp's laboratory services network and expands access to its clinical services BURLINGTON, N.C. and MIAMI , Sept. 16, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today the completion of Labcorp's acquisition of select assets of BioReference... Read More

BURLINGTON, N.C. , Sept. 3, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team will participate in a presentation at the Baird 2024 Global Healthcare Conference on Tuesday, September 10 , at 3:10 p.m. ET . About Labcorp Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory... Read More

Extends Labcorp's leadership in genetic testing solutions for oncology and select rare diseases BURLINGTON, N.C. , Aug. 5, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the completion of its acquisition of select assets of Invitae (OTC:NVTAQ), a leading medical genetics company. Together, Labcorp and Invitae will support patients, clinicians and... Read More

PGDx elio™ plasma focus Dx is the industry's first and only kitted, pan-solid tumor liquid biopsy test that enables tumor mutation profiling – all from a simple blood draw BURLINGTON, N.C. , Aug. 2, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it... Read More

Updates Full-Year Guidance Results from Continuing Operations for second quarter 2024 versus last year: Revenue: $3.22 billion versus $3.03 billion Diluted EPS: $2.43 versus $1.74 Adjusted EPS: $3.94 versus $3.42 Free Cash Flow: $432.9 million versus $58.2 million Updated Full-Year 2024 Guidance: Revenue range of 6.4% to 7.5%, includes Invitae impact of ~1.0% Adjusted EPS range of $14.30 to $14.90 , includes Invitae dilution... Read More

BURLINGTON, N.C. , and FREMONT, Calif. , July 29, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with Ultima Genomics to utilize its UG 100 TM sequencing solution and ppmSeq TM technology to explore new whole genome sequencing (WGS) clinical applications, including molecular residual disease (MRD) in patients with... Read More

BURLINGTON, N.C. , July 25, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on September 13, 2024 , to stockholders of record as of the close of business on August 29, 2024 . About Labcorp Labcorp (NYSE: LH) is a global leader... Read More

BURLINGTON, N.C. , July 1, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2024 before the market opens on Thursday, August 1, 2024 . The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial... Read More

Suite of digital and data solutions designed to improve clinical trial efficiency, reduce data delays and simplify investigator site workflows BURLINGTON, N.C. , June 17, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp Global Trial Connect, a suite of central laboratory solutions aimed at increasing the speed of clinical... Read More

Labcorp® Tissue Complete, a comprehensive genomic profiling service, now available in Geneva and Shanghai to support global clinical trials Company expands leadership in liquid biopsy comprehensive genomic profiling for solid tumors with the integration of OmniSeq® INSIGHT circulating tumor DNA BURLINGTON, N.C. , June 3, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory... Read More

Abstracts offer insights into precision oncology diagnostics for triple-negative breast cancer, liquid biopsy and machine learning for tumor profiling BURLINGTON, N.C. , May 30, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will present several abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago ( May 31 – June 4, 2024 ).... Read More

BURLINGTON, N.C. , May 28, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team will participate in a presentation at the 44th Annual William Blair Growth Stock Conference on Tuesday, June 4 at 2:00 p.m. (CT) . About Labcorp Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory... Read More

Labcorp is now the only lab that can detect preeclampsia risk across all pregnancy trimesters BURLINGTON, N.C. , May 15, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of its first trimester preeclampsia screening test to be performed between 11 and 14 weeks gestation to determine the risk of developing preeclampsia before 34 weeks of... Read More

BURLINGTON, N.C. , May 8, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that its Annual Meeting of Shareholders will be webcast live on May 14 at 9:00 a.m. ET and can be viewed online on the Labcorp Investor Relations website . An archived replay of the webcast will be available for one year. About Labcorp Labcorp (NYSE: LH) is a global leader of... Read More

Acquisition advances Labcorp's specialty testing strategy in key areas such as oncology and rare diseases Key milestone reached in Invitae's Chapter 11 process BURLINGTON, N.C. and SAN FRANCISCO , May 7, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and Invitae (OTC:NVTAQ), a leading medical genetics company, announced today that the United States Bankruptcy... Read More

Assay expands company's leadership in precision medicine and cell and gene therapy BURLINGTON, N.C. , April 29, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the U.S. Food and Drug Administration (FDA) has approved its nAbCyte™ Anti-AAVRh74var HB-FE Assay, a companion diagnostic (CDx) to determine patient eligibility for treatment with BEQVEZ ™... Read More

Updates Full-Year Guidance Results from Continuing Operations for first quarter 2024 versus last year: Revenue: $3.18 billion versus $3.04 billion or up 4.6% | Base Business grew 6.7% Diluted EPS: $2.69 versus $2.34 Adjusted EPS: $3.68 versus $3.46 Full-Year 2024 Guidance: Raised midpoint and narrowed range of adjusted EPS to $14.45 to $15.35 ; Free Cash Flow remains $1.00 billion to $1.15 billion Year to date... Read More

Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 BURLINGTON, N.C. , April 24, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a... Read More

Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals $239 Million Cash Bid Includes Acquisition of Substantially All of the Company's Assets, Ensuring Business Continuity for Customers, Partners and Employees SAN FRANCISCO , April 24, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, announced that Labcorp (NYSE: LH), a global leader of... Read More

Innovative GFAP blood biomarker test expands Labcorp's portfolio of tests for diseases including Alzheimer's disease, multiple sclerosis, glioblastoma and brain injuries BURLINGTON, N.C. , April 15, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the availability of the nation's first test for glial fibrillary acidic protein (GFAP), a critical... Read More

BURLINGTON, N.C. , April 11, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on June 12, 2024 , to stockholders of record as of the close of business on May 28, 2024 . About Labcorp Labcorp (NYSE: LH) is a global leader of... Read More

The first at-home mpox testing kit provides patients with convenience and privacy to test for mpox, supports physicians in detection and treatment BURLINGTON, N.C. , April 10, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its Mpox PCR Test Home... Read More

Portfolio expansion solidifies company's commitment to advancing cancer research and patient care BURLINGTON, N.C. , April 8, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the strategic expansion of its precision oncology portfolio, solidifying its commitment to advancing cancer research and patient care on a global scale. The announcement... Read More

Labcorp Plasma Detect is the first clinically validated, whole-genome sequencing MRD solution for early-stage colon cancer BURLINGTON, N.C. , April 5, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp® Plasma Detect ™, the first clinically validated, tumor-informed, whole-genome sequencing circulating tumor DNA (ctDNA) molecular... Read More

Researchers to present on topics ranging from molecular residual disease and immunotherapy to whole-genome sequencing BURLINGTON, N.C. , April 2, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will present abstracts in the areas of immunology, cellular biology, genomics and liquid biopsy at the Annual Meeting of the American Association for Cancer Research ®... Read More

Longstanding partnership deepens with new financing, beta access to clinical manufacturing instruments, and AACR data presentations SAN FRANCISCO / Apr 01, 2024 / Business Wire / Xcell Biosciences Inc. (Xcellbio), an instrumentation company focused on cell and gene therapy applications, today announced it has added new elements to its research collaboration agreement with Labcorp, a global leader of innovative and... Read More

Expanded partnership to help increase patient access to critical genetic screening services including genetic counseling and test result turnaround time HOUSTON , March 29, 2024 /PRNewswire/ -- The Prelude Network ® (Prelude), the largest network of fertility clinics in North America , announced today an expansion of its partnership with Labcorp (NYSE: LH), a global leader of innovative diagnostic and biopharma laboratory... Read More

BURLINGTON, N.C. , March 27, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2024 before the market opens on Thursday, April 25, 2024 . The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial... Read More

Addition of pTau217 test further expands the company's leadership in testing options for Alzheimer's disease to improve patient care BURLINGTON, N.C. , March 20, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch and immediate availability of its test to identify the presence or absence of phosphorylated tau 217 ( pTau217 ), a pivotal blood... Read More

Outcomes point to value of biomarker testing in addressing testing gaps in clinical practice BURLINGTON, N.C. , March 16, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today presented the results from two studies at the 2024 SGO Annual Meeting on Women's Cancer. The studies demonstrate the value of biomarker testing in closing testing gaps and guiding targeted... Read More

New offering to support individuals and physicians with accessible and convenient testing options to guide weight loss management decisions and treatments BURLINGTON, N.C. , March 7, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the introduction of its Weight Loss Management portfolio. The new offering features educational resources and... Read More

Company Provides 2024 Guidance Results from Continuing Operations for the fourth quarter and full year versus last year: Revenue: Q4 of $3.03 billion vs $2.93 billion ; Full year of $12.16 billion vs $11.86 billion Diluted EPS: Q4 of $(1.95) vs $0.42 ; Full year of $4.33 vs $10.94 Adjusted EPS: Q4 of $3.30 vs $3.05 ; Full year of $13.56 vs $16.66 Free Cash Flow: Q4 of $414.2 million vs $508.1 million ; Full year of $748.7... Read More

NEW YORK and BURLINGTON, N.C., Feb. 07, 2024 (GLOBE NEWSWIRE) -- WeightWatchers (NASDAQ: WW), (“WeightWatchers,” “WW,” or the “Company”) today announced that Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, is deepening its existing partnership with WeightWatchers for Business to offer their full-spectrum weight health platform, with individualized pathways of both behavioral and... Read More

BURLINGTON, N.C. , Feb. 1, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, has once again been named to FORTUNE® magazine's list of the World's Most Admired Companies™, a recognition of the most respected and reputable companies globally. "Labcorp is honored to be included on this year's FORTUNE World's Most Admired Companies list," said Adam Schechter , chairman... Read More

B•R•A•H•M•S™ sFlt-1/PlGF KRYPTOR™ Test System is available through physicians and is the first FDA-cleared biomarker test to aid in the risk assessment of progression to preeclampsia with severe features, a leading cause of maternal and fetal mortality in the U.S. 1 BURLINGTON, N.C. , Jan. 31, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the... Read More

BURLINGTON, N.C. , Jan. 16, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth quarter and full year 2023 before the market opens on Thursday, February 15, 2024 . The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying... Read More

BURLINGTON, N.C. , Jan. 12, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 13, 2024 , to stockholders of record as of the close of business on February 27, 2024 . About Labcorp Labcorp (NYSE: LH) is a global leader of innovative and comprehensive... Read More

Collaboration Aims to Improve Patient Experience, Accessibility and Efficiency in Decentralized Clinical Trials BURLINGTON, N.C. and LAFAYETTE, Calif. , Jan. 10, 2024 /PRNewswire/ -- Labcorp , a global leader of innovative and comprehensive laboratory services, and Hawthorne Effect, Inc. , a complete clinical trials solution integrating technology, are pleased to announce a strategic collaboration to advance decentralized... Read More

BURLINGTON, N.C. , Jan. 2, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team will participate in a fireside chat at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 9 at 4:30 p.m. (PT) . A live audio webcast of the fireside chat will be available via the Company Investor Relations... Read More

Agreement Expands Access to Labcorp's Diagnostics Capabilities and Services BURLINGTON, N.C. , Nov. 20, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the completion of the previously announced transaction with Legacy Health to acquire select assets of Legacy's outreach laboratory business. Labcorp also now manages Legacy's inpatient hospital... Read More

BURLINGTON, N.C. and WASHINGTON , Nov. 16, 2023 /PRNewswire/ -- Today, the Tigerlily Foundation (Tigerlily), a leading breast cancer patient advocacy organization, and Labcorp , a global leader of innovative and comprehensive laboratory services, announced the launch of I AM INCLUDED , a co-developed, modernized, multi-stakeholder framework for sharing best practices of U.S. diverse clinical trial site leaders for inclusive... Read More

Expanded offering adds inclusive end-to end support for pre-conception, adoption and surrogacy while removing barriers to equitable care access BOSTON , Nov. 8, 2023 /PRNewswire/ -- Ovia Health by Labcorp (Ovia) today announced it will offer a first-of-its-kind Fertility and Family Building Benefit, providing companies and health plans a comprehensive and customizable solution to support the diverse family-building journeys... Read More

Company Updates Full-Year Guidance Third quarter revenue grew 6.6% versus last year as the Base Business grew 14.0%. Results from Continuing Operations for third quarter versus last year: Revenue: $3.06 billion versus $2.87 billion Diluted EPS: $2.11 versus $3.06 Adjusted EPS: $3.38 versus $4.01 Free Cash Flow: $170.6 million versus $170.2 million Full-Year 2023 Guidance from Continuing Operations: Adjusted EPS of $13.25 to... Read More

BURLINGTON, N.C. , Oct. 12, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on December 12, 2023 , to stockholders of record as of the close of business on November 8, 2023 . About Labcorp Labcorp (NYSE: LH) is a global leader... Read More

Test is available through physicians for use with patients being evaluated for possible Alzheimer's disease or other causes of cognitive impairment Labcorp is the first company to deliver a blood-based Amyloid-Tau-Neurodegeneration (ATN) Profile, which uses a trio of blood biomarkers to detect the hallmarks of Alzheimer's disease BURLINGTON, N.C. , Oct. 11, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of... Read More

Labcorp to acquire Baystate Health's outreach laboratory business and select operating assets Collaboration to improve access and enhance affordable, high-quality healthcare services for underserved communities across Massachusetts BURLINGTON, N.C. , Oct. 4, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will acquire Baystate Health, Inc.'s... Read More

BURLINGTON, N.C. , Sept. 29, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the third quarter of 2023 before the market opens on Thursday, October 26, 2023 . The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial... Read More

BUFFALO, N.Y. , Sept. 27, 2023 /PRNewswire/ -- Graves Gilbert , a multispecialty clinic comprised of more than 200 providers representing over 30 medical specialties in Bowling Green, Kentucky , and surrounding counties, is proud to announce a collaboration with Circuit Clinical , an integrated research organization, to bring clinical trials to patients in South Central Kentucky. The partnership supports broader efforts to... Read More

BURLINGTON, N.C. , Sept. 14, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, is hosting an Investor Day beginning at 1:00 p.m. ET today in New York City , expected to conclude by approximately 4:00 p.m. ET . The event will highlight the company's go-forward strategy from Labcorp Chairman & CEO Adam Schechter , followed by business overviews and a longer-term... Read More

Labcorp Expands Diagnostic Testing and Laboratory Services in Eastern Massachusetts to Increase Access, Affordability and Standardized Testing Labcorp and Tufts Medicine have entered into an agreement for Labcorp to acquire the Tufts Medicine Outreach Laboratory Business and select operating assets This transaction – an initial component of an envisioned larger strategic partnership – will expand patient specimen collection... Read More

BURLINGTON, N.C. , July 31, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced it will host an Investor Day on Thursday, September 14, 2023 , in New York City , beginning at 1:00 p.m. ET and is expected to conclude by approximately 4:00 p.m. ET . This event will highlight Labcorp's go-forward strategy from Labcorp Chairman & CEO Adam Schechter ,... Read More

Company Provides Full-Year Guidance Labcorp completed the spin-off of Fortrea on June 30 , which is treated as discontinued operations in the historical financials Announced a $1.0 billion accelerated share repurchase program Drove growth through new and expanded healthcare system partnerships Second quarter revenue grew 4% versus last year as the Base Business grew 13%. Results from Continuing Operations for second quarter... Read More

Labcorp's Menopause Test and Menopause Support Program provide women with insights to guide their healthcare decisions BURLINGTON, N.C. , July 24, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it now offers menopause testing through its Labcorp OnDemand digital health platform. Approximately 1.3 million women enter menopause each year. While... Read More

BURLINGTON, N.C. , July 13, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader in innovative and comprehensive laboratory services, today announced the completion of the previously announced transaction that establishes a strategic relationship with Jefferson Health ( Jefferson ), the largest health system serving the greater Philadelphia and Southern New Jersey region. "This groundbreaking agreement between Jefferson... Read More

BURLINGTON, N.C. , July 13, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on September 8, 2023 , to stockholders of record as of the close of business on August 8, 2023 . About Labcorp Labcorp (NYSE: LH) is a global leader of innovative and comprehensive... Read More

Agreement Will Expand Access to Labcorp's Diagnostics Capabilities and Improve Services BURLINGTON, N.C. , July 11, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that it has entered into an agreement with Legacy Health to acquire select assets of its outreach laboratory business, including laboratory facilities and equipment. Labcorp will also... Read More

Company completes spin-off from Labcorp and begins trading on Nasdaq under ticker “FTRE” Independent company positioned to capitalize on growth opportunities in phases I-IV clinical trials and patient access, and to extend leading positions in oncology, clinical pharmacology and partnership models DURHAM, N.C., July 03, 2023 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research... Read More

BURLINGTON, N.C. , July 3, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that it has completed the spin-off of Fortrea, the newly formed independent Contract Research Organization providing Phase I-IV clinical trial management, patient access and technology solutions to pharmaceutical and biotechnology organizations around the world. Fortrea will... Read More

BURLINGTON, N.C. , June 29, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the second quarter of 2023 before the market opens on Thursday, July 27, 2023 . The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the... Read More

NEW YORK , June 28, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Thursday, July 6 : Fortrea Holdings Inc. (NASD:FTRE) will replace Seneca Foods Corp. (NASD:SENEA). S&P 500 constituent Laboratory Corporation of America Holdings (NYSE:LH) is spinning off Fortrea Holdings in a transaction expected to be completed on July 3.... Read More

BURLINGTON, N.C. , June 14, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, is pleased to share that its executive vice president and chief marketing officer, Amy Summy , has been awarded the inaugural Forrester Customer Obsession Leadership Award, recognizing senior executives who put customers at the center of everything they do to accelerate business growth, retain customers and enable... Read More

BURLINGTON, N.C. , June 12, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced that Fortrea Holdings Inc., a wholly owned subsidiary of Labcorp ("Fortrea"), has priced an offering of $570 million of senior secured notes due 2030 (the "Notes"), in connection with the previously announced spinoff of Fortrea into a separate publicly traded company (the "Spinoff"). The Notes will... Read More

BURLINGTON, N.C. , June 12, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, previously announced the following record and distribution dates for its spin-off of Fortrea Holdings Inc., a wholly owned subsidiary of Labcorp ("Fortrea"): The record date will be 5:00 p.m. Burlington, North Carolina time on Tuesday, June 20, 2023 , and The distribution date will be 11:59 p.m. Burlington, North... Read More

BURLINGTON, N.C. , June 9, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced the following record and distribution dates for the spin-off of Fortrea Holdings Inc., a wholly owned subsidiary of Labcorp ("Fortrea"): The record date will be 5 p.m. Burlington, North Carolina time on Tuesday, June 20, 2023 , and The distribution date will be 11:59 p.m. Burlington, North Carolina time... Read More

BURLINGTON, N.C. , June 8, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced that Fortrea Holdings Inc., a wholly owned subsidiary of Labcorp ("Fortrea"), has launched an offering of senior secured notes due 2030 (the "Notes"), subject to market conditions and other customary factors, in connection with the previously announced spinoff of Fortrea into a separate publicly traded... Read More

Health system executive brings three decades of medical enterprise experience to Labcorp BURLINGTON, N.C. , June 7, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced the appointment of Dr. Paul Rothman to its Board of Directors as an independent member. Dr. Rothman's appointment is effective June 6, 2023 , at which time the Board will expand to 12 directors, 11 of whom are... Read More

BURLINGTON, N.C. , June 5, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced Fortrea, the new company to be formed by the planned spin-off of Labcorp's Clinical Development and Commercialization Services business, will host its inaugural Investor Day on Tuesday, June 6, 2023 , in New York City at 9 a.m. ET . This event will review Fortrea's business, operational outlook, growth... Read More

Liquid biopsy test for cancer patients enables oncologists to identify targeted therapies and improve care BURLINGTON, N.C. , May 31, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, has launched Labcorp Plasma Focus, a new liquid biopsy test enabling targeted therapy selection for patients with advanced or metastatic solid tumors. The test allows treating oncologists to evaluate circulating... Read More

Patients and Providers in Oregon Region Will Gain Broader Access to Labcorp's Diagnostic Testing and Laboratory Services Labcorp and Providence Health & Services – Oregon (Providence Oregon) have entered into an agreement for Labcorp to acquire select assets of Providence Oregon's outreach laboratory business Providence Oregon will maintain ownership of certain anatomic pathology and genomics outreach testing and hospital... Read More

BURLINGTON, N.C. , May 4, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced that its Annual Meeting of Shareholders will be webcast live on May 11 at 9:00 a.m. ET and can be viewed online on the Labcorp Investor Relations website . An archived replay of the webcast will be available for one year. About Labcorp Labcorp is a leading global life sciences company that provides vital... Read More

Physicians and Patients Will Gain Access to Enhanced Laboratory Services and Advanced Diagnostic Testing Labcorp will acquire select assets of Jefferson's outreach laboratory services Jefferson will continue to own and operate their existing hospital labs for outpatient and inpatient services BURLINGTON, N.C. , May 3, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced an... Read More

Company Updates Full-Year Guidance First quarter Base Business revenue grew 10%, while total revenue and earnings were down due to COVID-19 Testing Revenue: Q1 of $3.8 billion versus $3.9 billion last year Diluted EPS: Q1 of $2.39 versus $5.23 last year Adjusted EPS: Q1 of $3.82 versus $6.11 last year Free Cash Flow: Q1 of $27 million versus $239 million last year Planned spin of Clinical Development business remains on... Read More

BURLINGTON, N.C. , April 6, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on June 8, 2023 , to stockholders of record as of the close of business on May 18, 2023 . About Labcorp Labcorp is a leading global life sciences company that provides vital... Read More

Partnership will distribute screening kits to communities at higher risk of colon cancer BURLINGTON, N.C. , April 3, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, is partnering with the Conference of National Black Churches (CNBC) to address health equity gaps in colorectal cancer screening. To raise awareness and provide expanded access to colorectal cancer screening tests, the Conference... Read More

BURLINGTON, N.C. , March 31, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the first quarter of 2023 before the market opens on Tuesday, April 25, 2023 . The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the... Read More

BOSTON / Feb 22, 2023 / Business Wire / Ovia Health , a trusted digital health platform for women and families, today announced the expansion of its Ovia® app, which will now allow women to track menopause symptoms and access valuable resources and support to address the transition to menopause/perimenopause. The technology is available through Ovia’s consumer application and enterprise offerings for employers and health... Read More

BURLINGTON, N.C. / Feb 16, 2023 / Business Wire / Labcorp (NYSE: LH), a leading global life sciences company, today announced results for the fourth quarter and year ended Dec. 31, 2022, full-year 2023 guidance. “We finished the year strong, with accelerated revenue growth in Diagnostics, continued strong underlying fundamentals in Drug Development and margin expansion,” said Adam Schechter, chairman and CEO of Labcorp. “In... Read More

BURLINGTON, N.C. / Feb 09, 2023 / Business Wire / Labcorp (NYSE: LH), a leading global life sciences company, today announced that the new company to be formed by the planned spin-off of its Clinical Development business will be known as Fortrea. Upon completion of the spin-off from Labcorp, Fortrea will operate as an independent, publicly traded global CRO that offers comprehensive drug and medical device development... Read More

Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the fourth quarter and full year 2022 before the market opens on Thursday, Feb. 16, 2023. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website . The... Read More

Labcorp (NYSE: LH), a leading global life sciences company, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 13, 2023, to stockholders of record as of the close of business on Feb. 23, 2023. About Labcorp Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical... Read More

Mr. Pike Brings 30 Years of Industry Experience and a Proven Track Record of Driving Growth Labcorp (NYSE: LH), a leading global life sciences company, today announced that Thomas (Tom) Pike will join Labcorp as president and chief executive officer of its Drug Development Clinical Development business unit on Jan. 9, 2023. Until the planned spin-off of the Clinical Development business, which is expected to occur in... Read More

Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a fireside chat at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10 at 4:30 p.m. (PT). A live audio webcast of the fireside chat will be available via the Company Investor Relations website at ir.Labcorp.com and archived for replay. About Labcorp Labcorp is a... Read More

New Space Will Be Three Times Larger and Increase Testing Capabilities BURLINGTON, N.C.--( BUSINESS WIRE )-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has begun operations at a new, larger anatomic pathology and histology (APH) laboratory in Los Angeles, expanding the company’s global... Read More